Delivery Order SPE2DB24D2101-SPE2DB25FKKHG
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $43,249.13 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (30-count packages) on July 18, 2025, with an ultimate completion date of July 21, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. Gemtesa is a prescription medication used in the treatment of overactive...
- The Defense Logistics Agency awarded a delivery order valued at $1,747.33 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (30-count units) on August 11, 2025, with completion scheduled for August 12, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Gemtesa is a prescription medication used to treat overactive bladder symptoms,...
- The Defense Logistics Agency awarded a $45.5K delivery order to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (30-count units) on August 4, 2025, with completion scheduled for August 5, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 6, 2025, for the supply of Gemtesa 75 mg tablets (90-count packages) with a ceiling value of $40,767.56. This firm fixed-price delivery order, which must be completed by June 9, 2025, represents a child contract under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The award was competitively procured with no set-aside designation and will be performed at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units) under a firm fixed-price contract valued at $8,109.88. The award was made on July 18, 2025, with an ultimate completion date of July 21, 2025. This delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Gemtesa is a prescription...
- The Defense Logistics Agency awarded a delivery order valued at $32,547.85 to AmerisourceBergen Drug Corp for 90-count tablets of Gemtesa 75 mg on August 14, 2025, with completion scheduled for August 15, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Gemtesa is a pharmaceutical product used in the treatment of overactive bladder, representing one...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $2,376.00 to supply Gemtesa 75 mg tablets (90-count packaging) with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed price delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance is listed...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) valued at $19,403.29. This firm fixed-price delivery order, with an ultimate completion date of August 15, 2025, represents a non-competitive set-aside award and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $7,772.26 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Gemtesa 75 mg tablets (30-count units). The contract represents a firm fixed price, non-set-aside award with an ultimate completion date of September 4, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) on August 8, 2025, with a ceiling value of $3,831.81 and an ultimate completion date of August 11, 2025. This non-set-aside, competitively awarded delivery order utilizes firm fixed pricing and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKKHGDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 7, 2025, for the supply of Gemtesa 75 mg tablets (90-count package) with a ceiling value of $26,882.44. This firm fixed-price delivery order, which carries an ultimate completion date of May 8, 2025, represents a non-competitive set-aside transaction and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Gemtesa is a prescription medication used to treat overactive bladder symptoms, reflecting the breadth of pharmaceutical products that AmerisourceBergen supplies to federal medical procurement programs. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. As a prime vendor for the Defense Logistics Agency's medical supply chain, AmerisourceBergen serves as a critical supplier of pharmaceuticals and medical commodities to military healthcare systems, the Defense Health Agency, and other federal healthcare organizations. The company's established relationship with DLA, demonstrated through its comprehensive prime vendor contract, positions it to fulfill ongoing medical supply needs across therapeutic domains while supporting global military healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.9k | 5/7/25 |